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in BMI (p\0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (-5.9 mmHg, p\0.001), diastolic blood pressure (-3.2 mmHg, p\0.001), LDL cholesterol (-0.189 mmol/l, p\0.001) and triglycerides (-0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of -1.0% in HbA 1c (p\0.001) and a reduction in weight (-4.5 kg, p\0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of -1.08% in HbA 1c (p\0.001) and a weight reduction of 
INTRODUCTION
Liraglutide is a GLP-1 receptor agonist (GLP1RA) which induces a significant improvement in glycemic control, body weight and cardiovascular risk factors. Its use is costeffective when the clinical indicators and the total costs associated with type 2 diabetes mellitus (type 2 DM) management are analyzed [1] . Current recommendations prioritize the selection of antidiabetic treatments with low risk of hypoglycemia, and also recommend considering the effects of antidiabetic drugs on weight when selecting a treatment [2, 3] . The presence of hypoglycemic events resulted in increased use of health-care resources [4] , so the selection of antidiabetic treatment with a low risk of hypoglycemia may result not only in an improvement in the quality of life, but also in a reduction in costs [4] . Considering these findings, in a recent position paper from the Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition [5] , the use of GLP1RA as a second-or third-line therapy is recommended in type 2 DM patients with obesity due to its low risk of hypoglycemia and its additional effects beyond the improvement in glycated hemoglobin (HbA 1c ) and weight.
The efficacy and safety of liraglutide both as mono-and combination therapy have been evaluated in the Liraglutide Effect and Action in Diabetes (LEAD) program, where liraglutide induced a decrease of HbA 1c between 0.8% and 1.5% [6] [7] [8] [9] [10] . In addition, liraglutide leads to a reduction in weight and also in blood pressure and lipids [11] . Due to its additional effects on glycemic control, liraglutide is associated with an improvement in life expectancy and in quality-adjusted life expectancy. It is also associated with a reduced cost in diabetes-related complications, so it is more cost-effective versus a DPP4 inhibitor [12] .
A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under artificial conditions and in a very limited and highly selected patient population.
Consequently, there is uncertainty regarding whether the results obtained can be generalized to the diverse patient populations encountered in everyday clinical practice, and whether these results can be generalized to standard care.
Reports about real-life effects of liraglutide have been published recently [13] [14] [15] [16] [17] .
However, some of them have included a scarce number of patients treated with GLP1RA [13] [14] [15] . Thus, the confirmation of these results in other countries and other populations is still necessary. In this study, we provide data about the effectiveness of liraglutide treatment in a real-life and clinical practice setting in Spain.
METHODS
This is a multicenter, retrospective and observational study. Data from type 2 DM patients were recorded through an online tool (eDiabetes-Monitor, available at www. diabetesmonitor.es) designed for recording data on clinical characteristics of type 2 DM patients in clinical practice and for providing tools (as dietetic and exercise recommendations) for the management of these patients. Patients with type 2 DM, aged 18 years or older and treated with GLP1RA, were included. Exclusion criteria were type 1 diabetes and refusal to provide informed consent. Due to the retrospective design, the criteria for the selection of concomitant treatment, escalation of the dose of GLP1RA and maintenance of the dose were not specified in the study protocol and were done prior to the inclusion of the patients and according to routine clinical practice at the discretion of the investigator.
From June 2011 to February 2014, 753 patients treated with GLP1RA were included. In the year prior to the initiation of the study, only exenatide and liraglutide were available in Spain. Thus, the majority of the patients included in the study (n = 740) were treated with liraglutide and 13 patients treated with exenatide were excluded from the analysis. The main data from the study were HbA 1c , weight and diabetes treatment before and after treatment with GLP1RA. Type 2 DM patients with at least two visits registered in the online tool (before the initiation of treatment and 3-6 months after that) and who had data about changes of HbA 1c , weight or both were selected for analysis (n = 684). Patients in whom the treatment for blood pressure or lipids was modified were excluded. After that, 539 patients had complete data of changes in lipid profile and 520 patients had complete data regarding changes in blood pressure. Data on adverse events including symptomatic hypoglycemia or severe hypoglycemia were also collected.
The study was approved by the ethical review Informed consent was obtained from all patients for being included in the study. 
RESULTS
Baseline characteristics of type 2 DM patients before starting liraglutide are shown in Table 1 .
After the initiation of treatment with liraglutide 0.6 mg and after the dose escalation, 26.5% of patients were treated with liraglutide 1.8 mg and the remaining 73.5% with 1.2 mg. There experienced a higher reduction in weight ( Fig. 1 ). When analyzing liraglutide effects of weight according to baseline BMI, the reduction in weight was higher in patients with higher baseline BMI (Fig. 2 ).
The decrease in HbA 1c showed significant differences according to the oral antidiabetic drugs (OADs) added on to liraglutide (Fig. 3 ). The reduction in weight was highest (-5.4 kg) in patients treated with metformin and it was significantly higher compared to patients treated with secretagogues (sulfonylurea or When we analyzed composite end points after liraglutide treatment, 48.3% of patients achieved an HbA 1c of 7% or less, 59.4% reached a weight reduction higher than 3% and in 28.1% both parameters were achieved (Fig. 4) .
Besides, in 36.3% of patients the reduction in weight was higher than 5%, and 9.2% of patients lost more than 10% of their initial weight. We also observed an improvement in the control of blood pressure and LDL cholesterol. In addition, 27.7% of patients reached an end point of controlled SBP and DBP and LDL \2.59 mmol/l (Fig. 4) . also induced a reduction of -4.5 kg (p\0.001) ( Fig. 5 ). In patients in whom DPP4 inhibitors were maintained after the initiation of liraglutide, HbA 1c decreased -1.28% and the weight reduction was -5 kg. However, there were no significant differences in the reduction of HbA 1c when DPP-4 inhibitors were switched off or maintained. In patients treated with insulin ± OADs, after add-on of liraglutide a reduction of -1.08% in HbA 1c and -4.15 kg was observed (p\0.001 for both) (Fig. 5 ). The change in HbA 1c and weight was higher when insulin and liraglutide were added to previous treatment (HbA 1c -1.43%, weight -7 kg) compared to switching from insulin to liraglutide ± OADs (HbA 1c -0.68%, weight -4.26 kg) ( Fig. 5) .
In patients previously treated with DPP-4 inhibitors, liraglutide in combination with
Regarding adverse effects, clinically significant gastrointestinal symptoms were recorded in seven patients. Only one patient discontinued the treatment, and the other six patients remained on treatment with a slower dose escalation. However, 68 patients (10%) who started liraglutide did not complete the two visits. We have no data regarding the reason for discontinuation, and we are aware that in many of these patients the reason may have been side effects, which will result in a similar percentage of side effects as have been reported in clinical trials. Hypoglycemic events were reported in 7.8% of patients. None of them were severe hypoglycemia. Hypoglycemic events were reported in 10.6% of patients treated with insulin and liraglutide, compared to 15.2% of patients treated with secretagogues and liraglutide (p = 0.369). In patients treated with liraglutide and metformin, the frequency of hypoglycemia was lower (1.6%) compared to patients treated with insulin or secretagogues (p\0.001 for both).
DISCUSSION
This study confirms the effectiveness of treatment with liraglutide in Spanish type 2 DM patients in a real-world setting. These data demonstrated a -1.1% mean reduction in HbA 1c and a decrease of -4.6 kg in weight. Treatment with liraglutide allows many patients to reach composite end points, with HbA 1c of less than 7% and a weight reduction higher than 3%. This was observed in 28.1% of patients after liraglutide treatment. The reduction in HbA 1c in our study was somewhat lower than the effect reported in the LEAD trials, which may be explained by a longer duration of the disease (10 ± 6 years) in the present study, compared to 7.7 years in LEAD studies. However, when analyzing real-life studies, the results of the present study are in line with previous data [13, 14] showing a reduction in HbA 1c between -1.23% and -1.5%, and a mean weight reduction between -2.9 and -4 kg. We did not find differences in HbA 1c or weight changes according to the dose of liraglutide, which is in contrast to previous results from LEAD trials [6, 8] . The presence of uncontrolled variables may have influenced these results, so no definite conclusions regarding the dose can be inferred from our data. In the LEAD program, weight changes were between -1.38 and -3.75 kg [6] [7] [8] [9] [10] . The mean weight reduction in this study was higher (-4.6 kg) which may be explained by higher mean weight compared to LEAD studies.
However, these results confirm previous retrospective data from the USA [17] , where a reduction in weight between 1.5 and 4 kg and a decrease of HbA 1c between 0.95 and 1.02% were observed.
We did not find differences in HbA 1c reduction according to diabetes duration or the number of OADs. However, after treatment with liraglutide as monotherapy, the reduction in HbA 1c and weight was in line with results from LEAD 3 study, where liraglutide monotherapy for 2 years provided significant effect on glycemic control and body weight compared with glimepiride monotherapy, at a lower risk of hypoglycemia [18] . In addition, in our study changes in BMI after liraglutide were After the initiation of insulin, an increase in hypoglycaemic episodes and weight occurs [22] , which may influence cardiovascular risk and is often a concern both for patients and physicians. Moreover, patients treated with insulin often do not achieve an adequate
HbA 1c [23] . Thus, our data indicates the utility of liraglutide in insulin-treated patients.
Our study has several limitations. First, due to the observational design, study visits were not strictly specified and the time between liraglutide initiation and laboratory data was more flexible. Secondly, clinical events and adverse events may not have been fully reflected by the study. Besides, due to the retrospective design, only patients with at least two visits (before and after liraglutide treatment) were included in the study, and probably the majority of patients with intense gastrointestinal adverse events were discontinued on their last visit. This fact probably has influenced the low rate of gastrointestinal symptoms reported in the present study, which is lower than that in previous data. Moreover, if we consider that in many of the 10% of patients who did not complete the two visits, the reason may be due to secondary effects, the percentage is similar to previous data from observational studies. In addition, the absence of data from patients with early withdrawal from liraglutide treatment and also in less adverse events, compared to those that would take place in the whole population of liraglutide-treated patients.
Finally, due to the heterogeneity of patient's characteristics, results from between group's comparisons should be interpreted with caution. On the other hand, the strength of our study is the size of the sample, which was larger than that of some of the previous observational studies. This may improve the reproducibility of the results when applying them to the general population.
CONCLUSION
Our study confirms the effectiveness of liraglutide in a real-world setting. In our cohort of patients with type 2 DM, treatment with liraglutide induced a significant reduction in HbA 1c , weight, lipids and blood pressure. Our results confirm the benefits observed in clinical trials. 
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